Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | 1.17% | 171.67 | 1.3% | $500.95m | |
| BIIB | Biogen Inc. | 1.30% | 235.95 | 1.3% | $485.51m | |
| CELG | Celgene Corporation | 0.17% | 96.41 | 1.3% | $469.40m | |
| GILD | Gilead Sciences, Inc. | 0.03% | 66.54 | 0.9% | $452.29m | |
| ILMN | Illumina, Inc. | 2.12% | 312.97 | 3.5% | $316.36m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 3.01% | 319.28 | 2.6% | $293.06m | |
| A | Agilent Technologies, Inc. | -0.32% | 68.10 | 1.6% | $199.31m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 2.45% | 173.26 | 1.9% | $181.93m | |
| EXAS | Exact Sciences Corporation | -1.45% | 95.54 | 25.3% | $168.34m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -0.66% | 127.95 | 2.0% | $150.45m | |
| BMRN | BioMarin Pharmaceutical Inc. | 0.38% | 87.80 | 4.3% | $118.15m | |
| SRPT | Sarepta Therapeutics, Inc. | 0.59% | 121.91 | 14.7% | $116.17m | |
| INCY | Incyte Corporation | 0.78% | 79.29 | 2.5% | $107.57m | |
| IONS | Ionis Pharmaceuticals, Inc. | -1.23% | 68.39 | 8.2% | $98.13m | |
| ALNY | Alnylam Pharmaceuticals, Inc | 0.62% | 68.29 | 9.2% | $96.21m |
Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.